These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 9122734)

  • 1. Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
    Thompson JA; Gold PJ; Fefer A
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S44-8. PubMed ID: 9122734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.
    Thompson JA; Gold PJ; Markowitz DR; Byrd DR; Lindgren CG; Fefer A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S29-34. PubMed ID: 9457390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.
    Legha SS
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S39-43. PubMed ID: 9122733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
    Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
    Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
    McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
    Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
    Keilholz U; Stoter G; Punt CJ; Scheibenbogen C; Lejeune F; Eggermont AM
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S22-8. PubMed ID: 9457389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
    Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
    Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
    In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
    Middleton MR; Lorigan P; Owen J; Ashcroft L; Lee SM; Harper P; Thatcher N
    Br J Cancer; 2000 Mar; 82(6):1158-62. PubMed ID: 10735499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
    Pyrhönen S; Hahka-Kemppinen M; Muhonen T; Nikkanen V; Eskelin S; Summanen P; Tarkkanen A; Kivelä T
    Cancer; 2002 Dec; 95(11):2366-72. PubMed ID: 12436444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
    Dutcher JP; Atkins M; Fisher R; Weiss G; Margolin K; Aronson F; Sosman J; Lotze M; Gordon M; Logan T; Mier J
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S73-8. PubMed ID: 9457399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen.
    Fierro MT; Bertero M; Novelli M; Appino A; Doveil GC; Colonna S; Bernengo MG
    Melanoma Res; 1993 Apr; 3(2):127-31. PubMed ID: 8518551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
    Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.
    Legha SS; Ring S; Eton O; Bedikian A; Plager C; Papadopoulos N
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S9-15. PubMed ID: 9457387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous interleukin-2 and interferon-alpha plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: a phase II study.
    Schmidt H; Geertsen PF; Fode K; Rytter C; Bastholt L; von der Maase H
    Melanoma Res; 2000 Feb; 10(1):66-77. PubMed ID: 10711642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?
    Hofmann MA; Sterry W; Trefzer U
    Jpn J Clin Oncol; 2007 Mar; 37(3):224-9. PubMed ID: 17472972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
    Tan EH; Ang PT
    Singapore Med J; 1996 Apr; 37(2):165-7. PubMed ID: 8942255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.